Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This review discusses the drug treatment of benign prostatic syndrome, highlighting the efficacy of combination therapies over monotherapies in patients at high risk for disease progression, but notes increased side effects and costs.

The researchers reported that using GoodRx.com enables patients to find the most affordable options for purchasing finasteride, a medication often not covered for androgenic alopecia, by comparing prices at local and mail order pharmacies in Washington, D.C.

Finasteride may cause weak ejaculation and reduced semen volume.

This study suggests that glaucoma patients may face increased risk of optic nerve injury if prescribed medications that can lower blood pressure.

This study found that terazosin, finasteride, or their combination were effective in treating symptoms of benign prostatic hyperplasia.

In this study, indications for monotherapy with 5-alpha-reductase inhibitors, such as finasteride and herbal drugs, were developed based on clinical and morphological changes in patients with benign prostatic hyperplasia.

In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.

Finasteride may help treat BPH by affecting certain biological markers.

This study found that combining longxuejie and finasteride effectively reduced intra-operative bleeding during TURP without side effects compared to finasteride, longxuejie alone, or control.

Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.

This study established a new reverse-phase high-performance liquid chromatography method to accurately and precisely quantify silodosin and dutasteride in mixtures, meeting International Council of Harmonization validation criteria for stability, sensitivity, and recovery.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This review evaluates existing preclinical and clinical studies on stromal vascular fraction for treating male sexual dysfunction, finding limited data and emphasizing the need for more research before conducting clinical trials.

This study presents a validated HPTLC method for simultaneously determining five BPH drugs, showing high sensitivity and selectivity for potential use in quality-control analysis.

This article reviews how various medications, such as antihypertensives, chemotherapy, and hormonal contraceptives, are associated with negative effects on sexual desire and function but reports no new clinical results.

This study concluded that locally manufactured finasteride tablets are bioequivalent to imported ones based on pharmacokinetic profiles in male volunteers.

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

Statins do not impact BPH and LUTS progression when combined with finasteride.

This study found that a substantial number of patients continued tamsulosin and/or finasteride unnecessarily after prostate surgery, with poor documentation and communication contributing to this issue.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.

This editorial examines the use of multiple drugs for treating lower urinary tract symptoms due to benign prostatic hyperplasia but offers no new research findings.

This study found that use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia was associated with an increased risk of erectile dysfunction.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

Man stopped medications due to sexual side effects, found relief with prostatic artery embolisation.